Autologous vein is the optimal conduit for peripheral arterial bypass surgery, a standard recently highlighted by findings from the BEST-CLI trial. The Human Acellular Vessel is a novel biologic conduit produced using regenerative medicine technologies with structural and mechanical properties like a human blood vessel. Not yet approved by the United States Food and Drug Administration, the Human Acellular Vessel is being studied as an alternative bypass conduit in patients with peripheral arterial disease, vascular injury, and those in need of arteriovenous access for hemodialysis. This report describes and illustrates the technical aspects of intraoperative handling specific to the use of this new and innovative technology.
Keywords: Arterial reconstruction; Bioengineered vessel; Chronic limb-threatening ischemia; Critical limb-threatening ischemia; HAV; Human acellular vessel; Peripheral arterial disease; Regenerative medicine.
© 2023 Published by Elsevier Inc. on behalf of Society for Vascular Surgery.